Related Experiment Video
Updated: Aug 11, 2026

Murine Prostate Micro-dissection and Surgical Castration
Published on: May 11, 2016
[Application of antiandrogens on prostatic diseases]
S Takahashi1, F Hasegawa, K Isurugi
1Department of Urology, Osaka Medical College.
Antiandrogen therapies show promise for benign prostatic hyperplasia (BPH) and prostate cancer, but sexual side effects require further investigation. New treatments combining pure antiandrogens with GnRH agonists are under development for advanced prostate cancer.
Area of Science:
- Endocrinology
- Urology
- Pharmacology
Context:
- Antiandrogen therapy is clinically utilized for benign prostatic hyperplasia (BPH) and prostate cancer.
- Steroidal antiandrogens, like progestational agents, inhibit prostate growth via pituitary gonadotropin suppression and direct androgen blockade.
- Sexual dysfunction is a significant side effect, particularly in BPH patients undergoing antiandrogen therapy.
Purpose:
- To review the current status and challenges of antiandrogen therapy in BPH and prostate cancer.
- To discuss the efficacy and side effects of steroidal and pure antiandrogens.
- To highlight ongoing clinical trials for novel antiandrogen treatments.
Summary:
- Steroidal antiandrogens suppress prostatic growth but can cause sexual dysfunction, especially in BPH patients.
- Pure antiandrogens, such as Flutamide and Casodex, are being investigated, including in combination with GnRH agonists for advanced prostate cancer.
- The efficacy of total androgen blockade therapy for advanced prostate cancer is still under investigation, with clinical trials ongoing in Japan.
Impact:
- Antiandrogen therapy offers a viable treatment option for BPH and prostate cancer.
- Addressing sexual side effects is crucial for improving patient compliance and quality of life.
- Ongoing research into novel antiandrogens and combination therapies may lead to more effective treatments for advanced prostate cancer.
Related Concept Videos
Adrenergic Receptors: ɑ Subtype
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Antihypertensive Drugs: Vasodilators
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...

